VERSIFEL FELV, SUSPENSION FOR INJECTION FOR CATS

Pajjiż: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

INACTIVATED SUB-UNIT ANTIGEN (GP70) OF FELINE LEUKAEMIA VIRUS (FELV) SUBTYPES A,B&C (KAWAKAMI-THEILEN STRAIN), QUIL A, CHOLESTEROL, DDA (DIMETHYL-DIOCTADECYL AMMONIUM BROMIDE), CARBOPOL

Disponibbli minn:

Zoetis Ireland Limited

Kodiċi ATC:

QI06AA01

INN (Isem Internazzjonali):

INACTIVATED SUB-UNIT ANTIGEN (GP70) OF FELINE LEUKAEMIA VIRUS (FELV) SUBTYPES A,B&C (KAWAKAMI-THEILEN STRAIN), QUIL A, CHOLESTER

Għamla farmaċewtika:

Suspension for Injection

Tip ta 'preskrizzjoni:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupp terapewtiku:

Feline

Żona terapewtika:

feline leukaemia virus

Indikazzjonijiet terapewtiċi:

Immunological - Inactivated vaccine

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2013-08-29

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Versifel FeLV,
suspension for injection for cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCE:
Inactivated feline leukaemia virus (FeLV) subtypes A,
B and C (Kawakami-Theilen strain) including gp70 sub-unit
antigen, inducing anti-gp70 antibodies
GMT
8.1 log
2
*
* As determined by mouse potency test (anti-gp70 antibodies, GMT
denotes: geometric mean titre)
ADJUVANTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
Slightly opaque suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunization of susceptible cats from 9 weeks of age to
reduce the number of cats infected with FeLV and
presenting clinical signs of the related disease.
No data are available in the studies to demonstrate protection against
related clinical disease but prevention of infection
is associated with protection against related clinical disease.
Onset of immunity occurs within four weeks of the completion of the
primary vaccination course.
The duration of immunity is at least one year after the primary course
and three years after the booster.
4.3 CONTRAINDICATIONS
None.
Quil A
20 µg
Cholesterol
20 µg
DDA (Dimethyl-dioctadecyl ammonium bromide)
10 µg
Carbomer
0.5 mg
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_9_
_/_
_0_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _